Our infographic spotlights key trends in the global market for cerebral aneurysm and arteriovenous malformation (AVM) embolization systems, which is expected to reach $1.2bn by 2022, a CAGR of 3.9% from $975m in 2017. Among the growth drivers is the improvement of imaging screening techniques in developed nations. While this has resulted in increased intervention for cerebral aneurysm and AVM embolization, routine screening is not practiced, even in developed nations. Embolic coils accounted for the majority of sales with an estimated 73% market share. Meanwhile, a growing number of improved and premium-priced products such coil-assisted stent products and advanced embolic coil designs and flow diversion products are driving up the total value of the market.
For a more in-depth look at the market, check out Meddevicetracker's report "Interventional Neurology: Cerebral Aneurysm and Arteriovenous Malformation Embolization Systems."
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Medtronic’s diabetes spin-out – a process likely to run up to 18 months and involve 20% IPO followed by a split-off for Medtronic shareholders – will allow firm to focus on higher-margin devices.
The FDA has stopped accepting data from two Chinese labs due to accuracy issues. Mid-Link and SDWH have been flagged for potentially falsified results and other misconduct. This decision, which follows months of discussions and warnings, emphasizes the FDA's commitment to ensuring data integrity in medical device submissions.
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.
